Evelo Biosciences Inc (EVLO)
Evelo Biosciences, Inc. is a clinical-stage biotechnology company focused on developing oral medicines designed to interact with immune cells in the small intestine and produce systemic effects. Its pipeline includes EDP1815, a whole-microbe candidate that has completed a Phase 2 study in psoriasis, as well as EDP1867, a non-live preparation based on a single strain of Veillonella parvula that is in Phase 1b testing. The company is also advancing EDP2939, an oral biologic being studied for inflammatory diseases, and EDP1908, a candidate under development for oncology. Evelo Biosciences was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The listed security is common stock on OTC Markets.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
OTC-EVLO
|
—
|
—
|
—
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
—
|
—
|
—
|
—
|
0.018 K
|
—
|
—
|
—
|
—
|
—
|
—
|
